Obiettivo By 2010 1.5 million stents per year will be deployed in Europe. Although outcome for patients has improved, stents still fail because of the occurrence of restenosis and thrombosis at the site of implantation. While drug eluting stents have helped to reduce the problem of restenosis, neointimal proliferation causing restenosis can still occur. Additional concerns exist regarding drug eluting stents as there appears to be a small but real increase in late and very late stent thrombosis, particularly after discontinuation of antiplatelet therapy.The novel concept we propose is use of a biodegradable magnetised stent (BMS) to deliver a novel biological therapy offering regenerative medicine solutions to the coronary artery vessel wall. Specifically we will develop the stent technology as a platform to attract autologous progenitor cells tagged in vitro with iron nanoparticles. Once deployed, the cells will be attracted to the already implanted BMS and proliferate to form a new endothelium. We will also use over-expression of the NRP1 gene in the artery wall where it will dimerise with NRP1 receptors on the deployed cells. The NRP1 gene will be transfected by adenovirus delivered from the wall of the BMS. Over time the BMS will undergo a predictable degradation to leave a wholly biological artery through regeneration of native tissues.Currently, about 12,000 European Citizens a year suffer from late in-stent thrombosis and 120,000 from restenosis. With the knowledge and technologies developed through the BIOMAGSCAR project we aim to halve this number of patients and save 66,000 people from unnecessary suffering, saving the European healthcare system €275 million p.a. in direct costs, only 10% of the total associated costs.Our consortium includes a vascular disease therapy company, a stent research and manufacturing company, four universities and a specialist in innovative technology investment, all of whom believe our technology will dramatically change this field. Campo scientifico medical and health sciencesclinical medicineangiologyvascular diseasesengineering and technologynanotechnologynano-materialsmedical and health sciencesbasic medicineimmunologyimmunotherapy Programma(i) FP7-HEALTH - Specific Programme "Cooperation": Health Argomento(i) HEALTH.2011.1.4-2 - Tools, technologies and devices for application in regenerative medicine Invito a presentare proposte FP7-HEALTH-2011-two-stage Vedi altri progetti per questo bando Meccanismo di finanziamento CP-FP - Small or medium-scale focused research project Coordinatore UNIVERSITY COLLEGE LONDON Contributo UE € 772 038,20 Indirizzo GOWER STREET WC1E 6BT LONDON Mostra sulla mappa Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Kimberly Cornfield (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Partecipanti (7) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto QUALIMED INNOVATIVE MEDIZINPRODUKTE GMBH Germania Contributo UE € 1 031 502,00 Indirizzo BOSCHSTRASSE 16 21423 WINSEN Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Georg Göllmann (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato TRIZELL LTD Partecipazione conclusa Regno Unito Contributo UE € 83 801,00 Indirizzo SANDERUM HOUSE 38 OAKLEY ROAD 0X39 4TW CHINNOR OXFORDSHIRE Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Russell Banks (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato ITA-SUOMEN YLIOPISTO Finlandia Contributo UE € 1 035 981,00 Indirizzo YLIOPISTONRANTA 8 70211 KUOPIO Mostra sulla mappa Regione Manner-Suomi Pohjois- ja Itä-Suomi Pohjois-Savo Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Tiina Reinikainen (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato MAGNUS INVENTION MANAGEMENT LTD Regno Unito Contributo UE € 601 353,00 Indirizzo GLASSLYN ROAD 39 N8 8RJ LONDON Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Mads Asprem (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato EURAM LIMITED Partecipazione conclusa Regno Unito Contributo UE € 319 687,80 Indirizzo LUCY TOWER STREET TOWER HOUSE LN1 1XW Lincoln Mostra sulla mappa Regione East Midlands (England) Lincolnshire Lincolnshire Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Andrew Banasik (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato QUEEN MARY UNIVERSITY OF LONDON Regno Unito Contributo UE € 478 005,00 Indirizzo 327 MILE END ROAD E1 4NS London Mostra sulla mappa Regione London Inner London — East Tower Hamlets Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Tanya Szendeffy (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato YALE UNIVERSITY Stati Uniti Contributo UE € 977 110,00 Indirizzo WHITNEY AVENUE 155 ROOM 214 06520 8337 New Haven Mostra sulla mappa Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Jeffrey Mcguinness (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Costo totale Nessun dato